Q-omics provides the consensus-scored DLGAP1-AS5 profile across patient tissues and cancer cell-line models. DLGAP1-AS5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, DLGAP1-AS5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, DLGAP1-AS5 RNA expression shows 9,390 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight THCA, and HNSC as cancer lineages where DLGAP1-AS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLGAP1-AS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLGAP1-AS5 survival associations across molecular data types. DLGAP1-AS5 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLGAP1-AS5 RNA expression–survival associations across cancer types. High DLGAP1-AS5 expression shows unfavorable associations in THCA, UCEC, THYM and KIRP, but favorable associations in MESO and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for DLGAP1-AS5 RNA expression.
This table summarizes DLGAP1-AS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DLGAP1-AS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLGAP1-AS5 shows lower tumor expression in HNSC, UCEC, KIRP and BRCA and higher tumor expression in COAD and LUAD. The HNSC box plot shows higher DLGAP1-AS5 RNA expression in normal versus tumor tissue (log2 FC = −1.263, t-test p < 0.001).
This table shows molecular features associated with DLGAP1-AS5 in patient tissues and cancer cell lines. In patient samples, DLGAP1-AS5 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
